Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

NCT05817903 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Axitinib
DRUG: Nivolumab

Sponsor

Consorzio Oncotech

Collaborators

[object Object]